New Delhi: The expert panel of Drug Controller General of India (DCGI) on Thursday recommended that emergency use authorization be granted to the COVID-19 vaccine Corbevax for children in the age group of 5 to 12 years.
Corbevax, developed by Hyderabad-based firm Biological-E, is India’s first indigenously-developed RBD protein sub-unit vaccine against the coronavirus.
It is being administered to children in the age group of 12 to 14 from March 16, 2022.
Meanwhile, the government panel has sought more data from Bharat Biotech before granting emergency use approval to Covaxin among children aged 5-12.
The 5-12 age group is yet to brought under the nationwide inoculation drive.
Bhubaneswar: The Nandankanan Zoological Park (NZP) near Bhubaneswar has received 11 species of animals and…
Mumbai: Abhishek Bachchan’s performance in Shoojit Sircar’s ‘I Want To Talk’ is being lauded by…
New Delhi: The Supreme Court on Monday dismissed pleas challenging the 42nd Amendment to the…
Berhampur: Fishermen helped a giant shark, which had got stuck on the beach in Sonapur…
Jajpur: Trouble seems to have mounted further for Bhaba Prasad Das, cousin of BJD organisational…
Perth: The writing was on the wall after India had reduced Australia to 12/3 in…
Bhubaneswar: Agitated locals staged a road blockade after a mini-truck of Omfed hit an auto-rickshaw,…
Bhubaneswar: Alarmed at growing ganja peddling in the state, the Odisha government has launched a…